Patients of open-angle glaucoma, secondary glaucoma, and preoperatively acute angle-closure glaucoma are no longer required to suffer from surgery delays due to high intraocular pressure(IOP). Diamox, X-GEN Pharmaceuticals has devised a new adjunctive treatment for lowering IOP.
Open angle glaucoma is a syndrome involving damage to the optic nerve with an open anterior chamber angle. It is also associated with inadequate aqueous humor drainage and leads to visual field loss, specifically in cases of optic nerve atrophy. Most of the patients with suffer from elevated or sometimes average interocular pressure.
Secondary glaucoma is a chronic glaucoma following an eye injury. It is often characterized by eye infection, inflammation, a tumor or enlarged cataract. Patients of secondary glaucoma also encounter dangerous buildup of internal eye pressure (intraocular pressure or IOP).
Acute angle closure glaucoma is associated with sudden or rapid rise in pressure inside the eye that is intraocular pressure. In such condition the iris or the colored part of the eye is pushed or pulled up against the trabecular meshwork( drainage channels) at the angle of the anterior chamber of eye. This blocks the flow of aqueous humor out of the eye, increasing the IOP in return.
High IOP is a major obstacle in surgeries. Lower IOP results in delaying the surgery. However, Diamox's new treatment is expected to lower the IOP within a short period so that surgery can be performed on time. The treatment essentially involves a sterile, preservative-free lyophilized powder. The vial incorporates acetazolamide sodium equivalent to 500 mg of acetazolamide and is packed in a single-vial cartons NDC# 39822-0190-1. It has to be stored at 20° to 25° C (68° to 77° F).
The new treatment comes as a relief for the patients with high IOP, as at present there is only one supplier of acetazolamide for injection USP. Launch of this product will not only ensure consistent and steady supply, rather it is also expected to lower the prices.